Article produced in association with London Pregnancy Clinic and Spital Clinic

Non-invasive prenatal testing has been part of antenatal care in the UK since the early 2010s.

In the years since its introduction, the test has undergone significant expansion in terms of what it can detect, how early it can be performed, and how its results are interpreted.

In 2026, NIPT is also beginning to incorporate artificial intelligence at the analysis stage.

This article explains what the test currently involves, what has changed, and what the phrase ‘AI NIPT’ actually refers to in clinical practice.

How Non-Invasive Prenatal Testing Works

From around nine weeks of pregnancy, small fragments of fetal DNA circulate in the maternal bloodstream. These are known as cell-free fetal DNA (cffDNA).

NIPT works by extracting this DNA from a maternal blood sample and analysing it to detect chromosomal differences in the fetus.

Because the test uses a maternal blood draw rather than sampling the placenta or amniotic fluid, it carries no risk of miscarriage.

It is a screening test rather than a diagnostic one, meaning a positive result requires confirmation through a diagnostic procedure such as CVS or amniocentesis.

NICE guidance on non-invasive prenatal testing, published as Diagnostics Guidance DG46, sets out the evidence for its use in detecting the three most common trisomies.

Currently, the NHS does not offer Non-Invasive Prenatal Testing (NIPT) to all pregnant individuals, but rather as a contingent or second-line test for a select group deemed at higher chance of carrying a baby with certain chromosomal conditions

What NIPT Can Now Detect

When NIPT was introduced, tests typically screened for trisomies 21, 18 and 13. Detection capabilities have expanded considerably since then.

Tests available in 2026 can screen for:

• All chromosomal trisomies and some monosomies across the 23 pairs of chromosomes
• Sex chromosome conditions including Turner syndrome (45,X) and Klinefelter syndrome (47,XXY)
• Microdeletions: small missing sections of chromosomes associated with conditions such as DiGeorge syndrome, Angelman syndrome and Prader-Willi syndrome
• Single-gene disorders, where parental carrier status has been established

Tests such as the KNOVA NIPT, for which London Pregnancy Clinic was the first UK provider, are now capable of screening for up to 100 conditions from a single blood draw.

This represents a substantial expansion from the three-trisomy scope of a decade ago.

What Has Changed in 2026

Three developments characterise the current state of NIPT in clinical practice.

First, testing is available earlier, with reliable results from nine weeks and some protocols beginning comprehensive genomic assessment from 10 weeks.

Second, expanded condition panels mean that families can choose the level of detection most appropriate for their situation, from basic trisomy screening to comprehensive genomic analysis.

Third, integrated prenatal pathways are becoming more common, combining NIPT with detailed anatomical scanning and genetics counselling rather than treating the test as a standalone investigation.

What AI NIPT Means in Practice

Artificial intelligence has entered NIPT analysis at the stage where raw cfDNA data is processed and interpreted.

Traditional NIPT analysis uses statistical models to compare the proportions of chromosomal DNA fragments in the maternal sample. AI-enhanced platforms apply machine learning to this process.

A study published in Frontiers in Genetics describes the development of an algorithm using cfDNA fragment distance analysis that improves accuracy by modelling the data in a more nuanced way than conventional statistical approaches.

In clinical practice, the most established AI NIPT platform is Panorama AI NIPT, which applies machine learning to cell-free DNA analysis to improve sensitivity and specificity for common aneuploidies and to extend detection to rarer variants.

The term ‘AI NIPT’ describes this category of platform, not a single product, and it is expected to become standard across major NIPT providers as the underlying technology matures.

The key clinical difference between AI-powered and conventional NIPT is not the type of conditions screened for but the quality of the analysis applied to the same data.

This translates to fewer false positives, fewer uninformative results and greater confidence in a negative finding.

Choosing Between Available Tests

The choice of NIPT should be guided by individual clinical circumstances and pre-test genetic counselling. For families with no known genetic risk factors, standard trisomy screening provides high accuracy at lower cost.

For those with a family history of genetic conditions or who have received an abnormal ultrasound finding, an extended panel or AI-powered test may be appropriate.

The Importance of Genetic Counselling

NIPT is a screening test and, like all screening tests, it produces a probability rather than a certainty. A positive result requires follow-up diagnostic testing before any clinical decisions are made.

A negative result substantially reduces risk but does not eliminate it. Understanding what results mean in both directions requires expert clinical input.

Pre-test counselling ensures that patients understand what they are consenting to; post-test counselling ensures that results are interpreted accurately and next steps are clear.

This is particularly important for expanded panels, where the clinical significance of some findings may be uncertain or variable in presentation.

Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.

Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.

This piece was produced in association with London Pregnancy Clinic and Spital Clinic, which provided background clinical information for editorial purposes.

Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.

The Femtech World Awards are celebrating the innovators revolutionising the way we diagnose and treat cancer in women.

Cancer is a major public health and economic issue.

Female breast cancer is the most commonly diagnosed cancer in the world, with an estimated 2.3 million cases diagnosed globally in 2020 alone.

However, what once seemed impossible in cancer research is now a reality thanks to a number of technological innovations that have led to breakthroughs in the ways we diagnose, understand and treat cancer.

Through the Women’s Cancer Innovation Award, Femtech World aims to shine a light on the organisations devoted to transforming the future of cancer care for women worldwide.

The Women’s Cancer Innovation Award is one of 10 categories open for entry, all of which seek to acknowledge excellence in femtech and reward the dedication, commitment and innovation of those working in the space. 

The Women’s Cancer Innovation Award is sponsored by Endomag.

Endomag believes everyone deserves a better standard of cancer care – that’s why they design their cancer localisation technologies with both the clinician and patient in mind.

Many leading hospitals across the world use their unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.

Their Magseed marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping.

Paired with the Sentimag localisation platform, they have now been widely proven across over 200 clinical studies, featuring more than 20,000 patients.

Entry for the Women’s Cancer Innovation award and all other categories closes on April 17.

Find out more and enter for free here.